Outcome of treatment for osteosarcoma of the extremities over the last 20 years: Report from 11 referral centers in Japan

Koichi Ogura, Hiroaki Hiraga, Takeshi Ishii, Toshifumi Ozaki, Yoshihiro Nishida, Hideo Morioka, Toru Hiruma, Takafumi Ueda, Nobuhito Araki, Norifumi Naka, Hirotaka Kawano, Akira Kawai

研究成果: Chapter

1 引用 (Scopus)

抄録

The survival of patients with osteosarcoma has improved dramatically due to the introduction of effective systemic chemotherapy. The key standard drugs for osteosarcoma chemotherapy are methotrexate, doxorubicin, and cisplatin, and multi-institutional trials based on these drugs have been conducted in Japan since the 1990s. However, there have been no nationwide data on treatment outcome, especially with regard to survival and prognostic factors. In this chapter, therefore, we present data from a large nationwide cohort of patients with osteosarcoma treated at 11 referral centers in Japan during the period 1990-2010 with special reference to survival and relevant prognostic factors. The 3-, 5-, and 10-year metastasis-free survival and overall survival rates for the 529 patients were 70 %, 64 %, and 62 % and 88 %, 83 %, and 77 %, respectively. The prognosis for patients with osteosarcoma in Japan was comparable to, or slightly better than, those reported in other countries. International collaboration should also be conducted in Asian countries including Japan to improve the outcome further and find the optimal treatment for osteosarcoma.

元の言語English
ホスト出版物のタイトルOsteosarcoma
出版者Springer Japan
ページ45-57
ページ数13
ISBN(電子版)9784431556961
ISBN(印刷物)9784431556954
DOI
出版物ステータスPublished - 2016 1 1

Fingerprint

Osteosarcoma
Japan
Referral and Consultation
Extremities
Survival
Drug Therapy
Methotrexate
Pharmaceutical Preparations
Doxorubicin
Cisplatin
Survival Rate
Neoplasm Metastasis

ASJC Scopus subject areas

  • Medicine(all)

これを引用

Ogura, K., Hiraga, H., Ishii, T., Ozaki, T., Nishida, Y., Morioka, H., ... Kawai, A. (2016). Outcome of treatment for osteosarcoma of the extremities over the last 20 years: Report from 11 referral centers in Japan. : Osteosarcoma (pp. 45-57). Springer Japan. https://doi.org/10.1007/978-4-431-55696-1_4

Outcome of treatment for osteosarcoma of the extremities over the last 20 years : Report from 11 referral centers in Japan. / Ogura, Koichi; Hiraga, Hiroaki; Ishii, Takeshi; Ozaki, Toshifumi; Nishida, Yoshihiro; Morioka, Hideo; Hiruma, Toru; Ueda, Takafumi; Araki, Nobuhito; Naka, Norifumi; Kawano, Hirotaka; Kawai, Akira.

Osteosarcoma. Springer Japan, 2016. p. 45-57.

研究成果: Chapter

Ogura, K, Hiraga, H, Ishii, T, Ozaki, T, Nishida, Y, Morioka, H, Hiruma, T, Ueda, T, Araki, N, Naka, N, Kawano, H & Kawai, A 2016, Outcome of treatment for osteosarcoma of the extremities over the last 20 years: Report from 11 referral centers in Japan. : Osteosarcoma. Springer Japan, pp. 45-57. https://doi.org/10.1007/978-4-431-55696-1_4
Ogura K, Hiraga H, Ishii T, Ozaki T, Nishida Y, Morioka H その他. Outcome of treatment for osteosarcoma of the extremities over the last 20 years: Report from 11 referral centers in Japan. : Osteosarcoma. Springer Japan. 2016. p. 45-57 https://doi.org/10.1007/978-4-431-55696-1_4
Ogura, Koichi ; Hiraga, Hiroaki ; Ishii, Takeshi ; Ozaki, Toshifumi ; Nishida, Yoshihiro ; Morioka, Hideo ; Hiruma, Toru ; Ueda, Takafumi ; Araki, Nobuhito ; Naka, Norifumi ; Kawano, Hirotaka ; Kawai, Akira. / Outcome of treatment for osteosarcoma of the extremities over the last 20 years : Report from 11 referral centers in Japan. Osteosarcoma. Springer Japan, 2016. pp. 45-57
@inbook{59fb0c9c0212405cbdc3752930667efc,
title = "Outcome of treatment for osteosarcoma of the extremities over the last 20 years: Report from 11 referral centers in Japan",
abstract = "The survival of patients with osteosarcoma has improved dramatically due to the introduction of effective systemic chemotherapy. The key standard drugs for osteosarcoma chemotherapy are methotrexate, doxorubicin, and cisplatin, and multi-institutional trials based on these drugs have been conducted in Japan since the 1990s. However, there have been no nationwide data on treatment outcome, especially with regard to survival and prognostic factors. In this chapter, therefore, we present data from a large nationwide cohort of patients with osteosarcoma treated at 11 referral centers in Japan during the period 1990-2010 with special reference to survival and relevant prognostic factors. The 3-, 5-, and 10-year metastasis-free survival and overall survival rates for the 529 patients were 70 {\%}, 64 {\%}, and 62 {\%} and 88 {\%}, 83 {\%}, and 77 {\%}, respectively. The prognosis for patients with osteosarcoma in Japan was comparable to, or slightly better than, those reported in other countries. International collaboration should also be conducted in Asian countries including Japan to improve the outcome further and find the optimal treatment for osteosarcoma.",
keywords = "Japan, Osteosarcoma, Prognosis, Prognostic factor",
author = "Koichi Ogura and Hiroaki Hiraga and Takeshi Ishii and Toshifumi Ozaki and Yoshihiro Nishida and Hideo Morioka and Toru Hiruma and Takafumi Ueda and Nobuhito Araki and Norifumi Naka and Hirotaka Kawano and Akira Kawai",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-4-431-55696-1_4",
language = "English",
isbn = "9784431556954",
pages = "45--57",
booktitle = "Osteosarcoma",
publisher = "Springer Japan",

}

TY - CHAP

T1 - Outcome of treatment for osteosarcoma of the extremities over the last 20 years

T2 - Report from 11 referral centers in Japan

AU - Ogura, Koichi

AU - Hiraga, Hiroaki

AU - Ishii, Takeshi

AU - Ozaki, Toshifumi

AU - Nishida, Yoshihiro

AU - Morioka, Hideo

AU - Hiruma, Toru

AU - Ueda, Takafumi

AU - Araki, Nobuhito

AU - Naka, Norifumi

AU - Kawano, Hirotaka

AU - Kawai, Akira

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The survival of patients with osteosarcoma has improved dramatically due to the introduction of effective systemic chemotherapy. The key standard drugs for osteosarcoma chemotherapy are methotrexate, doxorubicin, and cisplatin, and multi-institutional trials based on these drugs have been conducted in Japan since the 1990s. However, there have been no nationwide data on treatment outcome, especially with regard to survival and prognostic factors. In this chapter, therefore, we present data from a large nationwide cohort of patients with osteosarcoma treated at 11 referral centers in Japan during the period 1990-2010 with special reference to survival and relevant prognostic factors. The 3-, 5-, and 10-year metastasis-free survival and overall survival rates for the 529 patients were 70 %, 64 %, and 62 % and 88 %, 83 %, and 77 %, respectively. The prognosis for patients with osteosarcoma in Japan was comparable to, or slightly better than, those reported in other countries. International collaboration should also be conducted in Asian countries including Japan to improve the outcome further and find the optimal treatment for osteosarcoma.

AB - The survival of patients with osteosarcoma has improved dramatically due to the introduction of effective systemic chemotherapy. The key standard drugs for osteosarcoma chemotherapy are methotrexate, doxorubicin, and cisplatin, and multi-institutional trials based on these drugs have been conducted in Japan since the 1990s. However, there have been no nationwide data on treatment outcome, especially with regard to survival and prognostic factors. In this chapter, therefore, we present data from a large nationwide cohort of patients with osteosarcoma treated at 11 referral centers in Japan during the period 1990-2010 with special reference to survival and relevant prognostic factors. The 3-, 5-, and 10-year metastasis-free survival and overall survival rates for the 529 patients were 70 %, 64 %, and 62 % and 88 %, 83 %, and 77 %, respectively. The prognosis for patients with osteosarcoma in Japan was comparable to, or slightly better than, those reported in other countries. International collaboration should also be conducted in Asian countries including Japan to improve the outcome further and find the optimal treatment for osteosarcoma.

KW - Japan

KW - Osteosarcoma

KW - Prognosis

KW - Prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=85006716853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006716853&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-55696-1_4

DO - 10.1007/978-4-431-55696-1_4

M3 - Chapter

AN - SCOPUS:85006716853

SN - 9784431556954

SP - 45

EP - 57

BT - Osteosarcoma

PB - Springer Japan

ER -